Cardiological Society of India releases first Indian guidelines for dyslipidemia management

Dyslipidemia is a critical risk factor for cardiovascular diseases

Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention

Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population

Orchid Pharma and Cipla collaborate to launch antibiotic Cefepime-Enmetazobactam in India

The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR

Cipla gets 6 observations from USFDA for Goa facility

The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time

MediPharm Labs acquires advanced medical cannabis delivery method technology from Remidose Aerosols

Transaction is non-dilutive, with 100% performance-based payment through a royalty model

Ami Organics raises Rs. 400 crores through QIP

The Issue opened on June 18, 2024 and closed on June 21, 2024

Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide

Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024

Cipla EU to invest an additional € 3 million in Ethris

Cipla had earlier invested € 15 million in Ethris in 2022

Lupin and Fuji sign agreement for commercialization of Nextstellis in Vietnam and Philippines

Bristol Myers Squibb announces Opdivo Plus Yervoy (ipilimumab) improved overall survival for patients with unresectable hepatocellular carcinoma

Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population